Quidel Corporation (QDEL) saw its stock price surge 7.18% in pre-market trading on Monday, as investors reacted positively to a new trade agreement between the United States and China. The deal, which aims to reduce tariffs, has sparked a broad rally across the U.S. life sciences sector.

The agreement between the world's two largest economies is expected to significantly benefit U.S. life sciences firms, many of which have substantial business interests in China. By slashing tariffs, the deal could potentially lower costs and improve market access for these companies, leading to increased profitability and growth opportunities. Other major players in the sector also saw significant gains, with Bio-Techne up 6.1%, Bio-Rad Laboratories rising 5.9%, and Thermo Fisher Scientific climbing 4.7%.

Quidel, now known as QuidelOrtho following its merger with Ortho Clinical Diagnostics, has been a key player in the diagnostics market, particularly during the COVID-19 pandemic. The company's strong performance amid the sector-wide rally suggests that investors are optimistic about its potential to capitalize on the improved trade conditions with China. As the life sciences industry continues to evolve and expand globally, Quidel's position could be further strengthened by this latest development in international trade relations.